REVIEW

Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses

C. Garcia-Melendo,* X. Cubiró, L. Puig

Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain

Received 30 September 2020; accepted 21 December 2020

KEYWORDS
JAK/STAT pathway; Janus kinase inhibitors; Psoriasis; Atopic dermatitis

PALABRAS CLAVE
JAK/STAT; Inhibidores de JAK; Psoriasis; Dermatitis atópica

Abstract  Dermatologists’ interest in the Janus-associated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway has been growing as evidence builds to support its key role in the pathogenesis of inflammatory skin diseases. Because certain proinflammatory cytokines use the JAK/STAT pathway for signal transduction, it has become a promising therapeutic target in diseases where selective modulation of the immune system can be useful. We aim to review current knowledge of the JAK/STAT signaling pathway and its role in immune-mediated skin diseases. In the second part of the review we cover the efficacy and safety of oral and topical JAK inhibitors in the treatment of psoriasis, atopic dermatitis, and other skin diseases.

© 2021 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Inhibidores de JAK: usos en dermatología. Parte 2: aplicaciones en psoriasis, dermatitis atópica y otras dermatosis

Resumen  La vía de señalización de citocinas Janus cinasa/transductor de señal y activador de transcripción (JAK/STAT) es un área de interés emergente en dermatología, con evidencia creciente del papel clave en la patogénesis de las enfermedades inflamatorias cutâneas. Debido a que algunas citocinas proinflamatorias usan la vía JAK/STAT para la transducción de señales se convierte en una diana terapéutica prometedora para el tratamiento de dichas enfermedades al modular de forma selectiva el sistema inmune. El objetivo de esta revisión es conocer la vía
**Introduction**

Part 1 of this review provided a detailed description of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) intracellular signaling pathway. The potential role of JAK inhibitors in the treatment of various dermatologic diseases was highlighted, with emphasis on available evidence for vitiligo and alopecia areata.

Here, in Part 2, we review pathogenesis and the role of the JAK/STAT pathway in psoriasis and atopic dermatitis, as well as in other skin conditions such as hidradenitis, dermatomyositis, and graft-versus-host disease.

**Psoriasis**

The interleukin (IL) 23/IL-17 (IL-23/IL-17) axis is currently considered the main pathogenic pathway in psoriasis. However, several cytokines play a role in this disease, and some transmit their signal after binding to the corresponding receptors via the JAK/STAT pathway. These include interferon (IFN) γ, IFN-α, IL-2, IL-6, IL-12, IL-13, IL-19, IL-20, IL-21, IL-22, and IL-23. Tumor necrosis factor (TNF) α and other cytokines, such as IL-17, IL-8, and those of the IL-1 family (IL-1, IL-18, IL-36, and IL-38), do not directly activate the JAK/STAT pathway, although their activity can be suppressed indirectly through inhibition of the JAK/STAT pathway. 1-3

JAK signaling has been shown to be overregulated, with increased expression of STAT1 and STAT3 in lesional psoriatic skin when compared with healthy skin. 4-6

STAT1 is responsible for the transduction of type 1 IFN signals (α and β) and type 2 signals (γ) via a JAK1/JAK2–dependent mechanism, leading to production of multiple proinflammatory mediators and activation and maturation of dendritic cells with stimulation of type 1 helper T cells (Th1) and Th17. 7,8

STAT3 is involved in the induction and differentiation of Th17 cells via activation of JAK2/TKY2 induced by IL-23. 9 In addition, Th17 cells can produce IL-22, which is responsible for epidermal hyperplasia and production of antimicrobial peptides by keratinocytes. 2,10 STAT3 also participates in the proliferation of keratinocytes via IL-6–induced activation of JAK1/JAK2 or JAK1/TKY211,12 and is indirectly activated by IL-17 through induction of IL-19 and/or IL-36 by keratinocytes. 13

**Oral Tofacitinib**

Tofacitinib (Xeljanz, Pfizer) mainly inhibits JAK1 and JAK3. It has been approved by the United States Food and Drug Administration (FDA) for the treatment of adults with psoriatic arthritis and for the treatment of moderate to severe rheumatoid arthritis at doses of 5 mg twice daily. 14 It was recently approved for the treatment of polyarticular juvenile idiopathic arthritis in children aged 2–2 years, 15 as well as for treatment of ulcerative colitis at doses of 10 mg twice daily for 8 weeks and subsequently at 5 mg twice daily. 14,16

Tofacitinib has proven effective in moderate to severe psoriasis in phase 2 and 3 trials. In a study of 197 patients, treatment with tofacitinib 2 mg, 5 mg, and 15 mg twice daily achieved a Psoriasis Area and Severity Index 75 (PASI75) response rate of 25%, 41%, and 67%, respectively, at 12 weeks, compared with 2% for placebo. PASI90 was achieved at 12 weeks by 22% of those who received tofacitinib. 17

A phase 3 trial of 1106 patients with plaque psoriasis and PASI ≥12 revealed the noninferiority of tofacitinib 10 mg/12 h to subcutaneous etanercept 50 mg at week 12, with a similar rate of adverse events in each group. 18 Two phase 3 trials (Pivotal 1 [901 patients] and Pivotal 2 [960 patients]19), tofacitinib 10 mg/12 h was more efficacious than 5 mg/12 h from week 16 onward, with a greater PASI75 response rate between week 16 and week 28. Among the patients who reached PASI75 at week 16, the response was maintained at 52 weeks in 74.1% of the 5 mg/12 h group and 79.4% of the 10 mg/12 h group, and most continued to do so at 24 months. 20 In addition, at 16 weeks of treatment, both doses led to an improvement in ungual psoriasis, pruritus (the difference was evident 1 day after initiation of treatment), and the Dermatology Life Quality Index. The improvement was maintained at week 52. 21,22

Another phase 3 trial achieved an American College of Rheumatology (ACR) 20 response at week 16 in all patients with psoriatic arthritis treated with tofacitinib (5 mg/12 h or 10 mg/12 h) and an ACR50 or ACR70 in more than half. The responses were maintained at week 52. 21

Most adverse effects were mild or moderate. In the tofacitinib groups, 12 patients had herpes zoster, although the most frequent adverse effect was nasopharyngitis. 19 Two patients treated with tofacitinib 10 mg every 12 h in Pivotal 1 had severe infections (appendicitis, pneumonia, and pyelonephritis), whereas 3 patients who received tofacitinib 5 mg every 12 h in Pivotal 2 had severe infections (pneumonia, herpes zoster, erysipelas). Both studies reported an increase in cholesterol and creatine phosphokinase and reduced hemoglobin.

The adverse effects of tofacitinib are similar at 5 mg and 10 mg, with the most frequent being mild cytopenia, upper respiratory tract infections, headache, urinary tract infection, and diarrhea. 19,20,24 In October 2015, the FDA refused to approve tofacitinib for treatment of moderate to severe
plaque psoriasis, alleging that more studies were necessary on long-term safety.\(^\text{15}\)

**Topical Tofacitinib**

Topical tofacitinib could be an alternative therapy in mild to moderate plaque psoriasis. It has a favorable safety profile, although the improvement reported in published studies is slight. In a phase 2a study of 71 patients, the authors reported promising results with tofacitinib ointment 2% every 12 hours. The percentage change in the Target Plaque Severity Score at week 4 with respect to baseline was statistically significant with tofacitinib ointment compared with the vehicle (minimum mean score, \(-54.4\%\) vs. \(-41.5\%\), respectively).\(^\text{20}\) A subsequent multicenter randomized study including 435 patients who received tofacitinib ointment 1% and 2% revealed greater efficacy than the vehicle for treatment of psoriasis at week 8 (Physician’s Global Assessment [PGA] 0/1 in 18.6% of patients for tofacitinib 2% every 24 hours and 22.5% for tofacitinib 2% every 12 hours), although not at week 12. Reactions were observed at the application site in 8.1% of patients, although the highest incidence recorded for patients who received vehicle.\(^\text{27}\)

**Topical Ruxolitinib**

The JAK1/2 inhibitor ruxolitinib has been assessed as topical treatment for psoriasis. In a phase 2 clinical trial, 29 patients were randomized to receive ruxolitinib cream 0.5% or 1% once daily or 1.5% twice daily for 28 days, vehicle, or an active comparator (calcipotriene cream 0.005% or betamethasone dipropionate 0.05%). Treatment with ruxolitinib cream 1% and 1.5% was safe, well tolerated, and effective, with reduced plaque thickness, erythema, scaling, and lesion size compared with the vehicle (reduction of 53% in the treatment groups vs. 32% in the vehicle group). No significant differences in efficacy were found between ruxolitinib and the active comparators.\(^\text{18}\)

**Oral Baricitinib**

Baricitinib (Olumiant, Lilly) is a JAK1/2 inhibitor that has been approved by the FDA\(^\text{25}\) and the European Medicines Agency (EMA)\(^\text{30}\) for the treatment of moderate to severe rheumatoid arthritis at recommended doses of 4 mg/d. It was recently approved for the treatment of moderate to severe atopic dermatitis.\(^\text{30}\)

Baricitinib was studied in a phase 2b trial for treatment of moderate to severe plaque psoriasis in 271 patients. The PASI75 at week 12 was significantly higher for the groups treated with 8 mg and 10 mg once daily than for placebo (42.9%, 54.1%, and 16.1%, respectively). The most common adverse effects were infection, with an incidence rate of 26.5% in the placebo group and 21.5% in the baricitinib groups, the most common being nasopharyngitis.\(^\text{31}\)

**Oral Abrocitinib**

Abrocitinib (Pfizer) is a JAK1 inhibitor that was assessed for the treatment of moderate to severe psoriasis in a phase 2 trial lasting 12 weeks, in which 59 patients were randomly assigned to receive 200 mg/24 h, 400 mg/24 h, 200 mg/12 h, or placebo for 4 weeks. At week 4, the percentage of patients who achieved PASI75 was 17% for the placebo and 200 mg/24 h groups, 50% for the 400 mg/24 h group, and 60% for the 200 mg/12 h group. More laboratory abnormalities (low neutrophil, platelet, and reticulocyte counts) were observed in the 200 mg/12 h group, although no associated bleeding or severe infections were recorded.\(^\text{32}\)

**Oral Solcitinib**

A dose-dependent improvement in psoriasis was recorded with solcitinib (GlaxoSmithKline), a JAK1 inhibitor that was assessed in a phase 2 trial. The study population comprised 60 patients, of whom 13% achieved PASI75 at 100 mg/d, 25% at 200 mg/d, 57% at 400 mg/d, and 0% with placebo.\(^\text{33}\)

**Oral Itacitinib Adipate**

The JAK1 inhibitor itacitinib adipate (Incyte Corporation) led to a significant improvement in patients with moderate to severe psoriasis in a phase 2 trial including 50 patients and lasting 12 weeks. At 1 month, PASI75 was achieved by 0%, 11.1%, 0%, 22.2%, and 27.7% in the placebo, 100 mg/24 h, 200 mg/24 h, 200 mg/12 h, and 600 mg/24 h groups, respectively. The only significant differences with placebo were observed in the itacitinib 600 mg/d group.\(^\text{34}\)

**Oral Peficitinib**

Peficitinib (Smyraf, Astellas Pharma Inc.) is a pan-JAK inhibitor that has been approved in Japan for treatment of rheumatoid arthritis\(^\text{35}\) that proved efficacious in a phase 2 trial including 124 patients with moderate to severe plaque psoriasis. Patients received active treatment (10 mg, 25 mg, 60 mg, 100 mg twice daily or 50 mg once daily) or placebo. The mean improvement in PASI and body surface area with respect to baseline was significantly better in all treatment groups than in the placebo group at 6 weeks. The difference was dose-dependent.\(^\text{36}\)

**TYK2 Inhibitors**

Current studies focus on TYK2 inhibitors for the treatment of moderate to severe psoriasis.

The percentage of patients who reached PASI75 at 12 weeks in a phase 2 trial (267 patients) was significantly greater with deucravacitinib (a TYK2 inhibitor, Bristol-Myers Squibb) than with placebo (39% at 3 mg/24 h, 69% at 3 mg/12 h, 67% at 6 mg/12 h, and 75% at 12 mg/24 h vs. 7% in the placebo group). The PASI90 response rate was 43% at 12 weeks, and the PASI100 response rate was 25%.\(^\text{37}\)

The ongoing phase 3 trials with this drug (NCT04036435, NCT03924427) include one in which it is compared with apremilast (NCT03611751).\(^\text{38}\)

Breprocitinib (Pfizer) is a potent TYK2/JAK1 inhibitor that is being evaluated for treatment of psoriasis. In a phase 1 trial, 30 patients with moderate to severe plaque psoriasis received 30 mg or 100 mg orally or placebo once daily for 28
days. A PGA 0/1 response was achieved in 57.1%, 100%, and 0% of cases, respectively.\textsuperscript{11} Topical application of brepocitinib is currently being tested in a phase 2b trial in patients with mild to moderate psoriasis (NCT03850483\textsuperscript{22}).

Finally, another TYK2 inhibitor (PF-06826647, Pfizer) is being investigated for moderate to severe psoriasis in a phase 2 trial (NCT03895372\textsuperscript{23}).

**Atopic Dermatitis**

Atopic dermatitis is an inflammatory skin disease with a Th2-polarized immune response in its acute phase. The JAK/STAT pathway plays a key role in the dysregulation of the immune response in atopic dermatitis, including over-regulation of Th2, activation of eosinophils, suppression of regulatory T cells, and maturation of B cells, with differentiation to plasma cells and secretion of immunoglobulin (Ig) E, which binds to cutaneous mastocytes and leads to release of histamine. Similarly, the Th2 response leads to release of proinflammatory cytokines and proangiogenic factors by epidermal cells.

Atopic dermatitis is associated with an increase in signaling via JAK1, JAK2, JAK3, and TYK2\textsuperscript{26} (Fig. 1). JAK1, JAK3, and STAT6 are components of IL-4 signaling that are critical for Th2 cell differentiation\textsuperscript{45-47} and production of IL-4, IL-5, IL-10, and IL-13. STAT6 regulates the genes involved in Th2 cells and B-cell differentiation, switching from IgG to IgE, and production of class II major histocompatibility complex molecules. Various STAT6 polymorphisms have been associated with greater susceptibility to atopic dermatitis and high IgE levels.\textsuperscript{48}

The IL-4/IL-13/JAK/STAT pathway\textsuperscript{49} is important for the integrity of the skin barrier. Suppression by nonselective JAK inhibitors of STAT3 activation induced by IL-4/IL-13 has been shown to improve barrier function, thus promoting production of filaggrin and loricrin.\textsuperscript{50} Furthermore, IL-4 and IL-13 play a role in pruritus through their interaction with IL-4Rα and JAK1 in sensory neurons.\textsuperscript{51}

Factors other than IL-4 are important for differentiation of Th2. Thymic stromal lymphopoietin (TSLP) promotes Th2 cell differentiation, activates natural killer cells and basophils, and affects maturation of B cells. TSLP binds to a heterodimer composed of a TSLP receptor and an IL-7Rα receptor and induces phosphorylation of JAK1 and JAK2, leading to activation of STAT1, STAT3, and STAT5.\textsuperscript{52}

The spleen tyrosine kinase (SYK) pathway is also involved in the pathogenesis of atopic dermatitis. SYK is a cytoplasmic tyrosine kinase that is involved in signaling of proinflammatory cytokines and production of CCL20, which attracts Th17 cells to the skin.\textsuperscript{53,54} (Fig. 1). Inhibition of SYK suppresses this activation and has an anti-inflammatory effect, which may be synergic with concomitant inhibition of JAK. Favorable results have been reported for some dual inhibitors used to treat atopic dermatitis.

**Oral Tofacitinib**

An open-label study of 6 patients treated with tofacitinib 5mg once or twice daily, in addition to topical treatment, revealed a 36.6% reduction in the Scoring Atopic Dermatitis (SCORAD) score at weeks 8 to 12, and of 12% at week 29, with no remarkable adverse effects.\textsuperscript{55}

**Topical Tofacitinib**

Application of topical tofacitinib 2% (20mg/g) every 12 h in 69 patients with mild to moderate atopic dermatitis for 4 weeks led to an 81.7% reduction in the Eczema Area and Severity Index (EASI) score after 4 weeks, compared with 29.9% in patients receiving placebo. The Investigator Global Assessment (IGA), body surface area, and pruritus also improved from the first week of treatment.\textsuperscript{56}

**Oral Baricitinib**

Baricitinib (Olumiant, Lilly) has been evaluated in a phase 2 trial and in 2 phase 3 trials for treatment of moderate to severe atopic dermatitis.

Baricitinib was used concomitantly with topical triamcinolone 0.1% for 16 weeks in a phase 2 trial with 124 patients.\textsuperscript{57} Severity of atopic dermatitis improved significantly in those who received 2 mg and 4 mg compared with placebo, with a rapid improvement in pruritus during the first week and in health-related quality of life. In the group treated with baricitinib 4 mg, 61% of patients achieved an EASI50 response at 16 weeks compared with 37% in the placebo group.

In 2 phase 3 studies in adults (BREEZE-AD1 [624 patients] and BREEZE-AD2 [615 patients]), baricitinib improved the severity of atopic dermatitis at 16 weeks and led to a rapid reduction in pruritus from the first week. IGA 0/1 was reached in BREEZE-AD1 and BREEZE-AD2 at week 16, respectively, in 4.8% and 4.5% of patients in the placebo group and in 11.8% and 8.8% of the groups treated with baricitinib 1 mg, 11.4% and 10.6% in those treated with baricitinib 2 mg, and 16.8% and 13.8% of those treated with baricitinib 4 mg.\textsuperscript{58} The most common adverse events were nasopharyngitis, headache, and increased creatine phosphokinase. Long-term safety is currently being evaluated (NCT03334435).\textsuperscript{59}

Baricitinib was recently approved by the European Medicines Agency for treatment of moderate to severe atopic dermatitis in adult patients who were candidates for systemic treatment, with a recommended dose of 4 mg/d.\textsuperscript{30}

**Oral Upadacitinib**

Upadacitinib (Rinvoq, AbbVie) is a JAK1 inhibitor that has been approved for the treatment of rheumatoid arthritis.\textsuperscript{60} The efficacy and safety profile of the drug in adults with moderate to severe atopic dermatitis was evaluated in a phase 2b clinical trial. A total of 167 patients were randomly assigned to receive 3 different doses of upadacitinib (7.5 mg, 15 mg, and 30 mg daily) or placebo. The mean percentage improvement in the EASI at week 16 over baseline was higher than for placebo at all the doses of upadacitinib (39% for 7.5 mg, 62% for 15 mg, 74% for 30 mg vs. 23% in the placebo group). An EASI100 response was observed in 24% of
Figure 1  IL-4/IL-13/JAK/STAT signaling pathway and SYK pathway in atopic dermatitis. The figure shows various JAK inhibitors and dual JAK/SYK inhibitors in atopic dermatitis. The biological functions of IL-4 and IL-13 are mediated by their binding to the subunits IL-4Rα and IL-13Rα1 of the corresponding receptors. IL-4 binds to a type 1 receptor that includes IL-4Ra and the γ chain of the cytokine receptor or a type 2 receptor configured by IL-4Ra and IL-13Rα1. The latter is the main IL-13 receptor. IL-5 produced as a result of polarization of type 2 helper T cells binds to the IL-5Rα subunit of its receptor to form a complex with a shared signaling subunit, the β chain, and induce phosphorylation of JAK1/JAK2 and activation of STAT1, STAT3, and STAT5. Via its SH2 domains, SYK binds to diphosphorylated immunoreceptor tyrosine-based activation motifs (ITAM) in the cytoplasm of various immune receptors, such as T-, B-, NK-cell receptors or the various receptors for the constant fraction of immunoglobulin (Fc) in neutrophils, mastocytes, macrophages dendritic cells, and other strains of the immune system. This interaction results in the activation of other proteins that transmit downstream signals. Figure generated with the assistance of Biorender.com.

the patients treated with 30 mg/d, but not in those treated with placebo.

Results were recently published from 2 phase 3 trials, Measure Up 1 and Measure Up 2, which evaluate the efficacy and safety of upadacitinib for treatment of moderate to severe atopic dermatitis in adults and adolescents (NCT03569293 and NCT03607422). EASI75 was achieved at 16 weeks by 70% and 60% of the patients who received upadacitinib 15 mg (n = 281 [Measure Up 1] and n = 276 [Measure Up 2]), by 80% and 73% of those who received upadacitinib 30 mg (n = 285 [Measure Up 1] and n = 282 [Measure Up 2]), and by only 16% and 13% in the placebo group (n = 281 [Measure Up 1] and n = 278 [Measure Up 2]). IGA 0/1 was achieved by 48% and 39% of patients treated with upadacitinib 15 mg and 62% and 52% of those treated with upadacitinib 30 mg, compared with 8% and 5% of the placebo groups. Both doses led to an early reduction in pruritus, which remained unchanged at 16 weeks. The most common adverse effects were acne, nasopharyngitis, upper respiratory tract infection, and headache.63,64

The safety and pharmacokinetics of various doses of upadacitinib are being evaluated in children with severe atopic dermatitis (NCT03646604), and a phase 3 trial comparing upadacitinib with dupilumab in adults is currently underway (NCT03733970).

Oral Abrocitinib

Abrocitinib may be effective and well-tolerated in patients with moderate to severe atopic dermatitis.

A 12-week placebo-controlled phase 2b study included 269 adults treated with 4 daily doses of abrocitinib (10, 30, 100, and 200 mg). The EASI improved significantly compared with placebo only for 100 and 200 mg/d (reduction of 59% and 82.6% respectively vs. 35.2% in the placebo group), with a reduction in pruritus as early as day 2 of the study.65

In a recent phase 3 trial, 391 adolescents and adults were treated with abrocitinib 200 mg or 100 mg or placebo over 12 weeks. A greater percentage of patients in the abrocitinib 200 mg and 100 mg groups vs. placebo reached IGA 0/1 (38.1% and 28.4% vs. 9.1%, respectively), EASI75 (61% and 44.5% vs. 10.4%, respectively), and EASI90 (37.7% and 23.9% vs. 3.9%, respectively). Adverse effects were recorded in 65.8% of patients who received 200 mg, in 62.7% of the group that received 100 mg, and in 53.8% of the placebo group. The most frequent were nausea in the 200-mg group, nasopharyngitis in the 100-mg group, and atopic dermatitis in the placebo group. Severe adverse effects were observed in the abrocitinib 200 mg, 100 mg, and placebo groups, affecting 1.3%, 3.2%, and 1.3% of patients, respectively. The effects considered to be associated with treatment
included 1 case of herpangina and 1 case of pneumonia in the abrocitinib 100-mg group. Two patients in the abrocitinib 200-mg group developed herpes zoster, and 2 patients in the abrocitinib 100-mg group developed eczema herpeticum. Furthermore, in the group treated with 200 mg, the platelet count decreased in 2 patients, and thrombocytopenia was detected in 5 patients. 18

The long-term safety and efficacy profile of abrocitinib is being studied in adolescents (NCT03796676, NCT03627767, NCT03422822). Ongoing studies are comparing the efficacy of oral abrocitinib with subcutaneous dupilumab in adults with atopic dermatitis (NCT04345367, NCT03720470).

Oral Gusacitinib

Gusacitinib (Asana BioSciences) is a dual inhibitor of the JAK and SYK pathways that is currently being trialed as oral medication. In a phase 1b trial involving 36 patients, EASI50 was achieved and pruritus decreased in almost all patients at 4 weeks of treatment with 20, 40, or 80 mg. An EASI75 response was achieved in 63% of patients treated with 40 mg and in 50% of those treated with 80 mg/d compared with 22% in the placebo group. The improvement in the EASI response was associated with a decrease in the levels of the cutaneous biomarkers TNF2 and TNF2. 74

Results are pending from a phase 2b placebo-controlled trial to evaluate the efficacy and safety of ASN002 in 220 patients with moderate to severe atopic dermatitis (NCT03531957).

Topical Ruxolitinib

In a phase 2b trial, 307 patients with mild to moderate atopic dermatitis were randomized to receive ruxolitinib cream 1.5%/12 h, 1.5%/24 h, 0.5%/24 h, or 0.15%/24 h for 8 weeks, vehicle, or acetonide trimacinolone 0.1% cream every 12 hours for 4 weeks. A therapeutic benefit was recorded for all of the ruxolitinib regimens at week 4, although the regimen that led to the greatest change in EASI was ruxolitinib 1.5%/12 h (71.6% vs. 15.5% for vehicle). The improvement in EASI was greater in patients treated with ruxolitinib 1.5% every 12 hours or every 24 hours than in those treated with trimacinolone 0.1%, although the differences were not statistically significant. Furthermore, ruxolitinib managed to improve pruritis quickly. The improvement was maintained, the drug was well tolerated, and no relevant reactions were observed at the application site.

A phase 1 trial is currently evaluating the safety and pharmacokinetics of topical ruxolitinib in pediatric patients (NCT03257644), and other phase 3 trials include adolescents (NCT03745638, NCT03745651).

Topical Delgocitinib

The JAK1, JAK2, and JAK3 inhibitor delgocitinib (Corectim, Japan Tobacco/LEO Pharma) was developed for topical treatment of atopic dermatitis. 80 Phase 1 and 2 studies 71, 81 proved the concept of therapeutic efficacy with respect to severity and pruritus. Pruritus improved 1 day after initiating delgocitinib, probably owing to the inhibition of IL-31.

Results were recently published from a study that evaluated the safety and efficacy profile of delgocitinib 0.5% ointment in 158 Japanese patients aged ≥16 years with moderate to severe atopic dermatitis. The mean percentage change in EASI after 4 weeks was −44.3% in the delgocitinib group and 1.7% in the vehicle group; the results remained unchanged at 24 weeks. Various adverse effects were recorded, although these were mainly mild, affecting 4.7% of patients in the delgocitinib group and 1.9% in the vehicle group. The most common adverse effect was nasopharyngitis, followed by Kaposi varicelliform eruption and acne. 82

Topical delgocitinib 0.5% (Corectim) has been approved in Japan for treatment of atopic dermatitis. 84 Ongoing studies are evaluating various concentrations (NCT03725722) and include pediatric patients (NCT03826901).

Other Options

An ongoing study is evaluating the safety and efficacy profile of the JAK1 inhibitor SHR0302 (NCT04162899) for treatment of patients with moderate to severe atopic dermatitis. Results are pending from another study with topical brepotinib for treatment of mild to moderate atopic dermatitis (NCT03903822).

Other Applications in Dermatology

JAK inhibitors were recently used for the treatment of other treatment-refractory dermatologic conditions in which activation of the JAK/STAT pathway plays a key role (Table 1).

Conclusions

Dysregulation of the JAK/STAT pathway could intervene in the pathogenesis of many dermatologic diseases, including vitiligo, alopecia areata, psoriasis, and atopic dermatitis. JAK inhibitors, which have an acceptable safety profile, could be used for the simultaneous treatment of pathogenically similar inflammatory skin diseases with common signaling pathways.

In the case of moderate to severe psoriasis, tofacitinib has been evaluated in phase 1, 2, and 3 trials, all of which show it to be efficacious, especially at 10 mg/12 h, although the drug has not been approved by regulatory committees. Recent data suggest that TYK2 inhibitors could show promising results for the treatment of psoriasis. One such drug, deucravacitinib, has shown maximum efficacy for oral treatment of psoriasis. Current therapeutic options in atopic dermatitis are limited, although oral and topical JAK inhibitors have yielded promising results, with improvement in the severity of atopic dermatitis and a rapid and marked improvement in pruritus and quality of life. Baricitinib was recently approved for the treatment of moderate to severe atopic dermatitis in adults.

In the future, JAK inhibitors could prove to be a real alternative therapy for some inflammatory skin diseases. Selective inhibitors have a superior safety and efficacy pro-
<table>
<thead>
<tr>
<th>Disease</th>
<th>JAK Inhibitor</th>
<th>Study</th>
<th>Outcome</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatomyositis</td>
<td>Oral tofacitinib</td>
<td>Kurtzman et al. (2016)</td>
<td>- Clinical response at 4 wk</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 3 (2 with classic DM and 1 with amyopathic DM)</td>
<td>- Mean treatment period, 9.6 mo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tofacitinib 5-10 mg/12 h (1 patient received concomitant hydroxychloroquine)</td>
<td>- Mean improvement in CDASI score, 12 points</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wendel et al. (2019)</td>
<td>- Patient A: Stabilization of calcifications at 2 wk.</td>
<td>Patient A: Transient and moderate hypercalcemia, weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Calculifications stable or regressing at week 28, with no acral ulcers</td>
<td>Patient B: Weight gain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Patient B: Improvement in respiratory, cutaneous, and musculoskeletal symptoms. CDASI 10 at 12 wk. CDASI 3 at 28 wk, with no new</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>calculations and improvement or stabilization of previous calcifications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NCT03002649</td>
<td>- CDASI = 0 at 2 mo</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Recovery of muscle strength</td>
<td></td>
</tr>
<tr>
<td>Oral ruxolitinib</td>
<td></td>
<td>Hornung et al. (2014)</td>
<td>- Improvement in muscle pain, muscle strength, and skin lesions of DM at 4 mo. Regrowth of hair and eyebrows</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Stabilization of symptoms at 9 mo, with no signs of disease activity affecting the muscles, lungs, or skin</td>
<td>Development of small cell lung carcinoma. Discontinuation of ruxolitinib</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Disease</th>
<th>JAK Inhibitor</th>
<th>Study</th>
<th>Outcome</th>
<th>Safety</th>
</tr>
</thead>
</table>
| Cutaneous GVHD     | Oral ruxolitinib | Spoerl et al. (2014)\textsuperscript{95} \n \(n = 4\)  
- Patients with cutaneous GVHD refractory to 2 previous immunosuppressants and corticosteroids. Area affected 50\%  
- Oral ruxolitinib 10 mg/12 h | - Reduction of the affected area to < 25\%  
- Response in 1 wk and 1.5 wk | No adverse effects reported |
|                    |                  | Zeiser et al. (2015)\textsuperscript{96} \n - Retrospective study of 19 centers in Europe and the USA.  
 - 95 patients with corticosteroid-refractory GVHD (acute GVHD \(n = 54\), chronic GVHD \(n = 41\)), all moderate to severe.  
 - Ruxolitinib 5–10 mg/12 h | - Acute GVHD: the global response rate was 81.5\% (44/54), including 25 complete responses (46.3\%). Median time to response, 1.5 wk.  
- Chronic GVHD: overall response rate, 85.4\% (35/41); partial response 78\% (32/41); and complete response, 7.3\% (3/41). Median time to response, 3 wk.  
- Very satisfactory response in patients with skin involvement. | Cytopenia (55.6\% in the acute GVHD group and 17.1\% in the chronic GVHD group)  
Reactivation of CMV (33.3\% in acute GVHD and 14.6\% chronic GVHD) |
|                    |                  | Sarmiento et al. (2017)\textsuperscript{97} \n \(n = 8\)  
- GVHD refractory to corticosteroids and extracorporeal photopheresis. Acute GVHD, 3 patients (1 pulmonary, 2 cutaneous, 1 multisystemic); chronic GVHD, 5 patients (3 cutaneous)  
- Oral ruxolitinib, 10–20 mg/d | Response in 85\% and complete response in 50\% | 2 patients required dose reduction owing to grade 2 neutropenia |
| Oral itacitinib    | Ongoing trials:  
- Phase 2: NCT03491215 NCT02953678 NCT03616184  
- Phase 3: NCT02913261 NCT03112603 | No results available | No results available |
| Topical ruxolitinib| Ongoing trials  
Phase 1: NCT03497273  
Phase 2: NCT03846479  
Phase 3: NCT03584516 | No results available | No results available |
| Oral baricitinib   | Ongoing trials  
Phase 2 NCT03395340 | No results available | No results available |
<table>
<thead>
<tr>
<th>Disease</th>
<th>JAK Inhibitor</th>
<th>Study</th>
<th>Outcome</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidradenitis suppurativa</td>
<td>Oral tofacitinib</td>
<td>Savage et al. (2020)(^9) - n = 2</td>
<td>- Patient A: Reduced pain and number of lesions at 4 mo, enabling dose of ciclosporin to be reduced. No pain at 11 mo, with persistence only of inactive lesions</td>
<td>- Patient A. No adverse effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient A: Hurley stage III HS. Treated with tofacitinib 5 mg/12 h + amoxicillin 500 mg/12 h + ciclosporin 5 mg/kg</td>
<td></td>
<td>- Patient B: Reduction in number of admissions, improvement in ulcers</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient B: Hurley stage III HS. Tofacitinib 5 mg/12 h + amoxicillin-clavulanate 3 wk + azithromycin 1 wk + MMF 1250 mg/12 h + topical corticosteroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral INCB054707 (JAK1 inhibitor)</td>
<td></td>
<td>Ongoing trials Phase 2: NCT03607487 NCT03569371</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>Oral tofacitinib</td>
<td>Yang et al. (2018)(^9) - n = 10</td>
<td>- Clinical response in 8 patients (4 in monotherapy and 4 with adjuvant therapy)</td>
<td>Weight gain in 1 patient (4.5 kg at 12 mo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lichen planopilaris n = 10</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tofacitinib 10-15 mg/d for 2-19 mo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Adjuvant treatment: intralesional triamcinolone (2 patients), HCQ (1 patient), intralesional triamcinolone + HCQ (1 patient), intralesional triamcinolone + tacrolimus ointment (1 patient)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Damsky et al. (2020)(^10) - n = 3 with erosive lichen planus refractory to previous treatments (patient 1: prednisone, methylprednisolone; patient 2: methotrexate, mycophenolate mofetil, ciclosporin; patient 3: prednisone, acitretin).</td>
<td>- Patient A: Remission of symptoms and lesions Recurrence on suspending tofacitinib and MTX, improvement when tofacitinib was reintroduced</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tofacitinib 5 mg/12 h - Patient 1 received adjuvant therapy with MTX and PDN 10 mg daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous lupus erythematous</td>
<td>Topical ruxolitinib</td>
<td>Ongoing trials Phase 2 NCT03697460</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td></td>
<td>Oral ruxolitinib</td>
<td>Wenzel et al. (2016)(^11) - n = 1 Patient with primary myelofibrosis and chilblain lupus</td>
<td>Complete remission of skin lesions at 4 mo</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Ruxolitinib 20 mg/12 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease</td>
<td>JAK Inhibitor</td>
<td>Study</td>
<td>Outcome</td>
<td>Safety</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------</td>
<td>---------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pyoderma gangrenosum</td>
<td>Oral tofacitinib</td>
<td>Gregory et al. (2019) [103]</td>
<td>Lesion almost completely healed 3 wk after adding tofacitinib</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Oral tofacitinib</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg/12 h + infliximab</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg/kg (every 4 wk)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kochar et al. (2019) [104]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Crohn disease and refractory PG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Treated with tofacitinib 5–10 mg/12 h for severe</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>inflammatory arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wallace et al. (2018) [102]</td>
<td>No significant improvement observed in skin lesions.</td>
<td>Severe infection in 6% of the baricitinib 4 mg group, 2% of the 2 mg group, and 1% of the placebo group. Baricitinib led to dose-dependent reductions in hemoglobin, neutrophil, and triglyceride values and increase in platelet, CK, HDL cholesterol, and total cholesterol values</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 2 trial, 24 wk</td>
<td>Baseline CLASI 4.2, which is probably not sufficient to reveal</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 314, randomized to placebo, baricitinib 2 mg/d,</td>
<td>differences between the placebo and treatment groups.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>or baricitinib 4 mg/d (1:1:1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muco-cutaneous activity measured by SLEDAI-2K in</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>84%, although CLASI low</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Ongoing trials Phase 1: NCT03159936</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td>Chronic hand eczema</td>
<td>Topical delgocitinib</td>
<td>Ongoing trials Phase 2: NCT03683719 NCT02664805</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granuloma annulare</td>
<td>Oral tofacitinib</td>
<td>Damsky et al. (2019) [106]</td>
<td>Complete response in 2 patients</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tofacitinib 5 mg/12 h</td>
<td>One patient lost to follow-up after a 96% in CSAM1 at 4 mo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wallace et al. (2018) [107]</td>
<td>Complete response</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 1 trial, 34 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 30 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muco-cutaneous activity measured by SLEDAI-2K</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Ongoing trials</td>
<td>No results available</td>
<td>No results available</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Nasifoglu et al. (2018) [105]</td>
<td>Rapid improvement in PG and disappearance of lesion at 4 y</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Concomitant polycythemia vera with mutated JAK2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wallace et al. (2018) [107]</td>
<td>No adverse effects reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 3 trial, 36 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 30 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muco-cutaneous activity measured by SLEDAI-2K</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Damsky et al. (2019) [106]</td>
<td>Complete response in 2 patients</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tofacitinib 5 mg/12 h</td>
<td>One patient lost to follow-up after a 96% in CSAM1 at 4 mo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wallace et al. (2018) [107]</td>
<td>Complete response</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 1 trial, 34 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 30 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Wallace et al. (2018) [107]</td>
<td>Complete response in 2 patients</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 1 trial, 34 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 30 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral tofacitinib</td>
<td>Wallace et al. (2018) [107]</td>
<td>Complete response in 2 patients</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Phase 1 trial, 34 wk</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- n = 30 patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Patients with SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral ruxolitinib</td>
<td>Nasifoglu et al. (2018) [105]</td>
<td>Complete response in 2 patients</td>
<td>No adverse effects reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n = 1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Concomitant polycythemia vera with mutated JAK2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ongoing trials: information from ClinicalTrials.gov. [107]

Abbreviations. CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index; CK, creatine kinase; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; CMV, cytomegalovirus; CSAMI, cutaneous sarcoidosis activity and morphology instrument; DM, dermatomyositis; GVHD, graft-versus-host disease; HCQ, hydroxychloroquine; HS, hidradenitis suppurativa; SLE, systemic lupus erythematosus; LPPAI, Lichen Planopilaris Activity Index; MMF, mycophenolate mofetil; MTX, methotrexate; PDN, prednisone; PG, pyoderma gangrenosum; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2000.

* The table shows the studies performed or underway with JAK inhibitors for the treatment of various skin conditions, the main results obtained, and the safety of the drugs. Available evidence for JAK inhibitors is based mainly on case series, although clinical trials are ongoing.
file, whereas nonselective inhibitors are being developed mainly for topical use. The inhibition of multiple signals, especially the response to interferon, could increase susceptibility to infection and viral reactivation. While the safety and efficacy profile seems favorable for the moment, more studies are necessary to determine the doses that will optimize efficacy, cost-effectiveness, and safety of this drug family for potential use in skin conditions in the long term.

Conflicts of Interest

C. Garcia-Melendo declares that she has no conflicts of interest.

X. Cubiró has received fees from Novartis, Leo-Pharma, and Almirall.

L. Puig has received fees and/or has participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandzoz, Samsung-Bioepis, Sanofi, and UCB.

References

25. FDA declines to expand approval of Pfizer arthritis drug - Reuters [Internet]. Available from: https://www.reuters.com/article/pfizer-psoriasis-fda/fda-declines-to


38. Long-term study that measures the safety and efficacy of BMS-986165 in participants with psoriasis. – Full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04036435 [accessed 22.04.20].


40. An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03611751 [accessed 22.04.20].


62. A study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03607422 [accessed 03.05.20].


65. A study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03646604 [accessed 09.05.20].

66. A study to compare safety and efficacy of upadacitinib to dupilumab in adult participants with moderate to severe atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03738397 [accessed 09.05.20].


69. JAK1 inhibitor with mediated topical therapy in adolescents with atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03796676 [accessed 04.05.20].


71. Study to evaluate efficacy and safety of pf-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03422822 [accessed 09.05.20].

72. Study of abrocitinib compared with dupilumab in adults with moderate to severe atopic dermatitis on background topical therapy – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04345367 [accessed 09.05.20].

73. Study evaluating efficacy and safety of PF-04965842 and dupilumab in adult subjects with moderate to severe atopic dermatitis on background topical therapy – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03720470 [accessed 09.05.20].


75. Phase 2B study to evaluate ASNO02 in subjects with moderate to severe atopic dermatitis (RADIAN) – Full Text View – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03531957 [accessed 03.05.20].


77. A pharmacokinetic study of ruxolitinib phosphate cream in pediatric subjects with atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03257644 [accessed 03.05.20].

78. TRuE AD1 – An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis – Full Text View – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03745638 [accessed 09.05.20].

79. TRuE AD2 – an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03745651 [accessed 09.05.20].


85. Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. - Full Text View – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03725722 [accessed 09.05.20].

86. Delgocitinib cream for the treatment of moderate to severe atopic dermatitis during 8 weeks in adults, adolescents, and children – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03826901 [accessed 09.05.20].

87. A phase ii study in adult patients with moderate to severe atopic dermatitis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04162899 [accessed 04.05.20].


91. Study of tofacitinib in refractory dermatomyositis – full text view – ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03002649 [accessed 27.06.20].


93. Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib [Internet]. Available from: http://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3481 [accessed 24.05.20].


